<DOC>
	<DOCNO>NCT00081094</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , carbon-11 acetate positron emission tomography ( PET ) fludeoxyglucose F 18 PET , may improve ability detect hepatocellular carcinoma ( liver cancer ) allow doctor plan effective treatment . PURPOSE : This clinical trial study well carbon-11 acetate PET fludeoxyglucose F 18 PET work detect cancer patient liver cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Using Carbon-11 Acetate Fludeoxyglucose F 18 Detecting Hepatocellular Carcinoma ( Liver Cancer ) Patients With Known Suspected Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>INCLUSION : Biopsyproved HCC ( stage I II conventional staging ) one follow patient clinically document cirrhosis : AFP &gt; 200 mg/dL ; A contrastenhancing tumor mass ( &gt; 1 cm ) CT MRI ; A tumor mass confirm arteriography . Patient must provide write informed consent complete conventional image stag initiation PET imaging . EXCLUSION : Pediatric patient age 18 exclude consideration study . Patients know prior malignancy ( exception basal cell carcinoma skin carcinoma situ cervix ) within 5 year exclude entry study . However , patient prior HCC think new primary recurrent HCC eligible . Pregnant breastfeeding patient . Patients poorly control diabetes mellitus ( fast blood glucose level &gt; 200 mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
</DOC>